TCT CONNECT-92 Initial Single-Center Experience With Transfemoral Transcatheter Aortic Valve Replacement in Patients With Symptomatic Severe Aortic Regurgitation

Gogia, Shawn; Vahl, Torsten; Khalique, Omar; Hamid, Nadira; Borden, Sarah; Chung, Christine; Ng, Vivian G.; Patel, Amisha; George, Isaac; Hahn, Rebecca T.; Leon, Martin B.; Kodali, Susheel

doi:10.1016/j.jacc.2020.09.106

Cited by 4 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Initial single-center experience with 11 patients showed good results with no mortality or stroke at 30 days, but a rate of pacemaker implantation of 36.4%. Reduction in AR was significant, with only one patient with mild paravalvular leak [ 95 ]. The JenaValve is currently being tested in the ALIGN-AR pivotal trial (NCT04415047), a single-arm study including 180 high surgical risk patients with severe symptomatic AR.…”

Section: Where Are We Going?mentioning

confidence: 99%

Evolving Indications of Transcatheter Aortic Valve Replacement—Where Are We Now, and Where Are We Going

Mesnier

Panagides

Nuche

et al. 2022

JCM

View full text Add to dashboard Cite

Indications for transcatheter aortic valve replacement (TAVR) have steadily increased over the last decade since the first trials including inoperable or very high risk patients. Thus, TAVR is now the most common treatment of aortic valve stenosis in elderly patients (vs. surgical aortic valve replacement -SAVR-). In this review, we summarize the current indications of TAVR and explore future directions in which TAVR indications can expand.

show abstract

Section: Where Are We Going?mentioning

confidence: 99%

Evolving Indications of Transcatheter Aortic Valve Replacement—Where Are We Now, and Where Are We Going

Mesnier

Panagides

Nuche

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

Transcatheter aortic valve replacement for aortic regurgitation: a systematic review and meta‐analysis

Liu,

Fu,

Jiang

et al. 2024

ESC Heart Failure

View full text Add to dashboard Cite

The efficacy and safety of new‐generation devices (NGDs) for severe aortic regurgitation (AR) have mostly been based on single‐arm studies with limited sample sizes. Our goal was to summarize the current evidence on NGDs and compare the safety and efficacy of ‘off‐label’ and ‘on‐label’ devices in NGDs. We searched MEDLINE, Embase, Cochrane Library, and Scopus for articles on transcatheter aortic valve replacement in patients with AR. A total of 31 studies that included 1851 patients were identified through April 2023. Among these, 1067 (57.6%) patients received treatment with ‘on‐label’ devices (JenaValve and J‐Valve). For NGDs, the total device success rate at 30 days was 94.5% (on‐label: 97.8%, off‐label: 89.9%; P < 0.001), the all‐cause mortality was 4.2% (on‐label: 2.6%, off‐label: 5.1%; P = 0.006), permanent pacemaker implantation (PPI) was 8.8% (on‐label: 6.9%, off‐label: 18.4%; P < 0.001), and the rate of greater‐than‐mild paravalvular leak (PVL) was 1.2% (on‐label: 0.9%, off‐label: 3.8%; P = 0.003). On‐label devices showed significantly better safety and efficacy in terms of the success rate, PPI, greater‐than‐mild PVL, and 30 day mortality than off‐label devices.

show abstract

Meta-Analysis of Dedicated vs Off-Label Transcatheter Devices for Native Aortic Regurgitation

Samimi,

Hatab,

Kharsa

et al. 2024

JACC: Cardiovascular Interventions

View full text Add to dashboard Cite

TCT CONNECT-92 Initial Single-Center Experience With Transfemoral Transcatheter Aortic Valve Replacement in Patients With Symptomatic Severe Aortic Regurgitation

Cited by 4 publications

References 0 publications

Evolving Indications of Transcatheter Aortic Valve Replacement—Where Are We Now, and Where Are We Going

Evolving Indications of Transcatheter Aortic Valve Replacement—Where Are We Now, and Where Are We Going

Transcatheter aortic valve replacement for aortic regurgitation: a systematic review and meta‐analysis

Meta-Analysis of Dedicated vs Off-Label Transcatheter Devices for Native Aortic Regurgitation

Contact Info

Product

Resources

About